Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) were up 8.9% on Wednesday. The stock traded as high as $7.83 and last traded at $8.1590. Approximately 308,627 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 1,742,524 shares. The stock had previously closed at $7.49.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on KURA shares. JPMorgan Chase & Co. initiated coverage on Kura Oncology in a report on Thursday, October 1st. They set an "overweight" rating and a $30.00 target price on the stock. Citigroup restated a "market outperform" rating on shares of Kura Oncology in a report on Thursday, November 12th. Citizens Jmp reissued a "market outperform" rating and issued a $24.00 price target on shares of Kura Oncology in a report on Monday, August 24th. Wedbush increased their target price on shares of Kura Oncology from $36.00 to $38.00 and gave the company an "outperform" rating in a research note on Thursday, August 13th. Finally, Morgan Stanley set a $24.00 price target on shares of Kura Oncology in a research report on Monday, August 24th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kura Oncology has an average rating of "Moderate Buy" and a consensus price target of $25.88.
View Our Latest Research Report on KURA
Kura Oncology Stock Performance
The firm's 50 day moving average price is $9.95 and its 200-day moving average price is $9.76. The firm has a market cap of $686.80 million, a price-to-earnings ratio of -2.26 and a beta of 0.56. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.60 and a quick ratio of 3.56.
Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.78) earnings per share for the quarter, beating analysts' consensus estimates of ($0.82) by $0.04. The firm had revenue of $22.84 million during the quarter, compared to the consensus estimate of $24.94 million. Kura Oncology had a negative net margin of 369.26% and a negative return on equity of 336.24%. On average, analysts anticipate that Kura Oncology, Inc. will post -3.20 earnings per share for the current year.
Insider Buying and Selling at Kura Oncology
In other news, insider Mollie Leoni sold 28,802 shares of the firm's stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total value of $309,621.50. Following the transaction, the insider owned 141,095 shares of the company's stock, valued at approximately $1,516,771.25. This trade represents a 16.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Troy Wilson bought 101,119 shares of Kura Oncology stock in a transaction on Monday, November 16th. The shares were bought at an average price of $7.42 per share, for a total transaction of $750,302.98. Following the acquisition, the chief executive officer owned 635,456 shares of the company's stock, valued at approximately $4,715,083.52. The trade was a 18.92% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have acquired 300,000 shares of company stock valued at $2,743,765 and have sold 122,394 shares valued at $1,310,502. 7.60% of the stock is owned by insiders.
Institutional Investors Weigh In On Kura Oncology
Several large investors have recently made changes to their positions in KURA. Integrated Wealth Concepts LLC boosted its position in Kura Oncology by 45.1% during the third quarter. Integrated Wealth Concepts LLC now owns 20,982 shares of the company's stock valued at $225,000 after acquiring an additional 6,522 shares during the last quarter. Algert Global LLC bought a new position in shares of Kura Oncology in the 3rd quarter worth $13,976,000. Virtu Financial LLC acquired a new position in shares of Kura Oncology during the third quarter valued at about $225,000. New York State Common Retirement Fund increased its holdings in Kura Oncology by 38.0% during the 3rd quarter. New York State Common Retirement Fund now owns 29,795 shares of the company's stock worth $319,000 after purchasing an additional 8,200 shares in the last quarter. Finally, Jump Financial LLC lifted its stake in Kura Oncology by 738.8% during the 3rd quarter. Jump Financial LLC now owns 372,409 shares of the company's stock valued at $3,989,000 after acquiring an additional 328,009 shares in the last quarter.
About Kura Oncology
(
Get Free Report)
Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company's best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kura Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.
While Kura Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.